Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy.
Reustle A, Di Marco M, Meyerhoff C, Nelde A, Walz JS, Winter S, Kandabarau S, Büttner F, Haag M, Backert L, Kowalewski DJ, Rausch S, Hennenlotter J, Stühler V, Scharpf M, Fend F, Stenzl A, Rammensee HG, Bedke J, Stevanović S, Schwab M, Schaeffeler E.
Reustle A, et al. Among authors: haag m.
Genome Med. 2020 Mar 30;12(1):32. doi: 10.1186/s13073-020-00731-8.
Genome Med. 2020.
PMID: 32228647
Free PMC article.